STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORXA): KEY EVENTS DURING THE PERIOD Net revenues amounted to MSEK 21.7 (80.3) The loss after tax was MSEK 128.6 (loss: 20.5) Earnings per share amounted to a loss of SEK 9.24 (loss: 1.54) Orexo establishes a sales force in the Nordic markets by forming a joint venture with ProStrakan The EU registration process of Rapinyl® has been referred to EMEA’s Committee for Medicinal Products for Human Use (CHMP)
